Methotrexate Orion (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a key cofactor in the synthesis of DNA, RNA and proteins. By limiting these building blocks, the drug hampers the proliferation of rapidly dividing cells, including immune cells and malignant tumor cells.

The exact dose is set by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Dosing regimens differ between autoimmune diseases and oncologic protocols, and the prescriber will tailor the schedule to achieve optimal benefit while monitoring safety.

Methotrexate is classified as a teratogenic agent and its safety in pregnancy is not established. It is generally contraindicated for pregnant women and is not recommended during breastfeeding because it can be excreted in milk and may harm the infant. Effective contraception is advised for patients of reproductive potential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Methotrexate Orion. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Methotrexate is a folate antagonist, whereas other antimetabolites such as 5‑fluorouracil target thymidylate synthase. Compared with biologic agents used for rheumatoid arthritis, methotrexate is less expensive and administered by injection, but it requires regular laboratory monitoring for toxicity. Its broad oncologic activity also distinguishes it from many newer targeted therapies.

Methotrexate Orion should be stored in a refrigerated environment at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If a temporary temperature excursion occurs, consult the product’s stability guidelines before use.

The product is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique. The injection site and volume depend on the prescribed dose, and the medication may be given weekly or as part of a specific chemotherapy schedule.

The most critical adverse events include severe liver toxicity, pulmonary fibrosis, and profound bone‑marrow suppression that can lead to life‑threatening infections or bleeding. Renal impairment can also increase drug accumulation, raising the risk of toxicity. Patients should be monitored closely for signs of these serious complications.

Methotrexate Orion is contraindicated in patients with known hypersensitivity to methotrexate, severe hepatic disease, significant renal dysfunction, active infections, and in women who are pregnant or planning to become pregnant. It should also be avoided in individuals receiving live vaccines or those with uncontrolled immunodeficiency.